HIGH RISK LARGE B-CELL LYMPHOMAS
M.K. Gandhi, Brisbane (Australia), et al.
Authors Conclusion from the abstract: EBV+ CNSL in the immunosuppressed, have a tolerogenic TME with intact antigen presentation and expression of viral antigens, upregulated NFB signalling and absent CARD11 mutations. Results support combination strategies that cross the Blood Brain Barrier, to block NFB driven oncogenesis (ibrutinib), reconstitute EBV specific T cell immunity (3rd Party EBV specific CTL) and expand the TCR repertoire (ibrutinib). Findings led to an ALLG phase 1 clinical trial (ACTRN12618001541291).
S. Leppä, Helsinki (Finland), et al.
G.S. Nowakowski, Rochester, MN (USA), et al.
Authors Conclusion from the abstract: Durva + R‐CHOP combination therapy has an acceptable safety profile and demonstrates encouraging response rates in subjects with high‐risk DLBCL including double‐hit lymphoma.
M.S. Davids, Boston, MA (USA), et al.
Authors Conclusion from the abstract: Our initial data suggest that ven + da‐R‐EPOCH is a feasible regimen to treat RS. Expected toxicities from intensive chemoimmunotherapy were seen, without significant additional toxicity from ven, including no TLS with daily ven ramp‐up. The 67% CR and PFS/OS of 10/16.3 mo are favorable in the context of historical results. Accrual is ongoing, and updated results will be presented.
F. Morschhauser, Lille (France), et al.
Authors Conclusion from the abstract: Adding Ven to R‐CHOP improved efficacy in BCL2 IHC+ 1L DLBCL pts versus matched GOYA controls. A higher rate of cytopenia, FN and infection was observed in CAVALLI vs GOYA; however, there was no increase in risk of death and the RDI of chemotherapy was similar.
E.A. Chong, Philadelphia, PA (USA), et al.
Authors Conclusion from the abstract: At a median follow‐up over four years, we demonstrate that a single infusion of CTL019 provides durable remissions in pts with relapsed/refractory DLBCL and FL. This is the longest follow‐up for CTL019 therapy for relapsed/refractory B‐cell lymphomas reported to date.